F. Bibeau, E. Lopez-crapez, D. Fiore, F. Thezenas, S. Ychou et al., Impact of Fc {gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan, J Clin Oncol, vol.27, pp.1122-1129, 2009.

E. C. De-bruin, C. Cowell, P. H. Warne, M. Jiang, R. E. Saunders et al., Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer, Cancer Discov, vol.4, pp.606-619, 2014.

D. Burton and V. Krizhanovsky, Physiological and pathological consequences of cellular senescence, Cell Mol Life Sci, vol.71, pp.4373-4386, 2014.

D. R. Camidge, W. Pao, and L. V. Sequist, Acquired resistance to TKIs in solid tumours: learning from lung cancer, Nat Rev Clin Oncol, vol.11, pp.473-481, 2014.

J. Campisi, Senescence response to oxidative & genotoxic stress: a link between aging and disease, Free Radic Biol Med, vol.53, p.9, 2012.

S. Carvalho, F. Levi-schaffer, M. Sela, and Y. Yarden, Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18, Br J Pharmacol, vol.173, pp.1407-1424, 2016.

R. A. Clynes, T. L. Towers, L. G. Presta, and J. V. Ravetch, Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nat Med, vol.6, pp.443-446, 2000.

D. B. Costa and S. S. Kobayashi, Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M, Transl Lung Cancer Res, vol.4, pp.809-815, 2015.

G. P. Dimri, E. Hara, M. Acosta, P. Desprez, and J. Campisi, The role of P53 tumor-suppressor in cellular replicative senescence, FASEB J, vol.9, p.1464, 1995.

C. A. Eberlein, D. Stetson, A. A. Markovets, K. J. Al-kadhimi, Z. Lai et al., Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on ras signaling in preclinical models, Can Res, vol.75, pp.2489-2500, 2015.

S. Ellebaek, S. Brix, M. Grandal, J. Lantto, I. D. Horak et al., Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo-and heterodimers, Int J Cancer, vol.139, pp.2095-2105, 2016.

F. D. Di-fagagna, Living on a break: cellular senescence as a DNAdamage response, Nat Rev Cancer, vol.8, pp.512-522, 2008.

N. Gaborit, M. Lindzen, and Y. Yarden, Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3, Hum Vaccin Immunother, vol.3, pp.1-17, 2015.

Y. Gong, R. Somwar, K. Politi, M. Balak, J. Chmielecki et al., Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas, PLoS Med, vol.4, p.294, 2007.

A. N. Hata, M. J. Niederst, H. L. Archibald, M. Gomez-caraballo, F. M. Siddiqui et al., Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition, Nat Med, vol.22, pp.262-269, 2016.

A. Iannello, T. W. Thompson, M. Ardolino, S. W. Lowe, and D. H. Raulet, dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells, J Exp Med, vol.210, pp.2057-2069, 2013.

Y. Y. Janjigian, E. F. Smit, H. Groen, L. Horn, S. Gettinger et al., Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations, Cancer Discov, vol.4, pp.1036-1045, 2014.

P. A. Janne, J. C. Yang, D. W. Kim, D. Planchard, Y. Ohe et al., AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer, N Engl J Med, vol.372, pp.1689-1699, 2015.

G. M. Keating, Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer, Drugs, vol.74, pp.207-221, 2014.

S. Kobayashi, T. J. Boggon, T. Dayaram, P. A. Janne, O. Kocher et al., EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N Engl J Med, vol.352, pp.786-792, 2005.

A. Kol, A. Van-scheltinga, H. Timmer-bosscha, L. E. Lamberts, F. Bensch et al.,

E. Vries and C. P. Schroder, HER3, serious partner in crime therapeutic approaches and potential biomarkers for effect of HER3-targeting, 2014.

, Pharmacol Ther, vol.143, pp.1-11

B. Liao, C. Lin, and J. Yang, Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer, Curr Opin Oncol, vol.27, pp.94-101, 2015.

B. M. Lichtenberger, P. A. Gerber, M. Holcmann, B. A. Buhren, N. Amberg et al., Epidermal EGFR controls cutaneous host defense and prevents inflammation, Sci Transl Med, vol.5, pp.199-111, 2013.

A. Lujambio, L. Akkari, J. Simon, D. Grace, D. F. Tschaharganeh et al., Non-cell-autonomous tumor suppression by p53, Cell, vol.153, pp.449-460, 2013.

T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, vol.350, pp.2129-2139, 2004.

S. Mamidi, M. Cinci, M. Hasmann, V. Fehring, and M. Kirschfink, Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab, Mol Oncol, vol.7, pp.580-594, 2013.

M. Mancini, N. Gaborit, M. Lindzen, T. M. Salame, M. Dall'ora et al., Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer, The Authors EMBO Molecular Medicine, vol.8, issue.2, 2015.

M. Mancini and Y. Yarden, Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors, Semin Cell Dev Biol, vol.50, pp.164-176, 2015.

A. Marcus, B. G. Gowen, T. W. Thompson, A. Iannello, M. Ardolino et al., Recognition of tumors by the innate immune system and natural killer cells, Adv Immunol, vol.122, pp.91-128, 2014.

T. S. Mok, Y. L. Wu, S. Thongprasert, C. H. Yang, D. T. Chu et al., Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma, N Engl J Med, vol.361, pp.947-957, 2009.

T. S. Mok, Y. Wu, M. Ahn, M. C. Garassino, H. R. Kim et al., Osimertinib or platinumpemetrexed in EGFR T790M-positive lung cancer, N Engl J Med, vol.376, pp.629-640, 2017.

D. Munoz-espin and M. Serrano, Cellular senescence: from physiology to pathology, Nat Rev Mol Cell Biol, vol.15, pp.482-496, 2014.

A. Musolino, N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti et al., Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer, J Clin Oncol, vol.26, pp.1789-1796, 2008.

G. R. Oxnard, M. E. Arcila, J. Chmielecki, M. Ladanyi, V. A. Miller et al., New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer, Clin Cancer Res, vol.17, pp.5530-5537, 2011.

J. G. Paez, P. A. Janne, J. C. Lee, S. Tracy, H. Greulich et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, vol.304, pp.1497-1500, 2004.

W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi et al., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc Natl Acad Sci, vol.101, pp.13306-13311, 2004.

W. Pao, V. A. Miller, K. A. Politi, G. J. Riely, R. Somwar et al., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med, vol.2, p.73, 2005.

V. Pirazzoli, C. Nebhan, X. Song, A. Wurtz, Z. Walther et al., Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1, Cell Rep, vol.7, pp.999-1008, 2014.

D. Planchard, Y. Loriot, F. Andre, A. Gobert, N. Auger et al., EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients, Ann Oncol, vol.26, pp.2073-2078, 2015.

M. Ramirez, S. Rajaram, R. J. Steininger, D. Osipchuk, M. A. Roth et al., Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells, Nat Commun, vol.7, p.10690, 2016.

L. Regales, Y. X. Gong, R. L. Shen, E. De-stanchina, I. Vivanco et al., Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer, J Clin Investig, vol.119, pp.3000-3010, 2009.

R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal et al., Screening for epidermal growth factor receptor mutations in lung cancer, N Engl J Med, vol.361, pp.958-967, 2009.

A. Sagiv and V. Krizhanovsky, Immunosurveillance of senescent cells: the bright side of the senescence program, Biogerontology, vol.14, pp.617-628, 2013.

R. Salama, M. Sadaie, M. Hoare, and M. Narita, Cellular senescence and its effector programs, Genes Dev, vol.28, pp.99-114, 2014.

R. Sanders, D. J. Mason, C. A. Foy, and J. F. Huggett, Evaluation of digital PCR for absolute RNA quantification, PLoS One, vol.8, p.75296, 2013.

L. V. Sequist, R. L. Allen, and A. R. , Rociletinib in EGFR-mutated non-smallcell lung cancer, N Engl J Med, vol.373, pp.578-579, 2015.

M. Serrano, Cancer final act of senescence, Nature, vol.479, pp.481-482, 2011.

K. S. Thress, C. P. Paweletz, E. Felip, B. C. Cho, D. Stetson et al., Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat Med, vol.21, pp.560-562, 2015.

W. Xue, L. Zender, C. Miething, R. A. Dickins, H. E. Krizhanovsky et al., Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas, Nature, vol.445, pp.656-660, 2007.

J. Yang, M. Ahn, D. Kim, S. S. Ramalingam, L. V. Sequist et al., Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component, J Clin Oncol, vol.35, pp.1288-1296, 2017.

T. A. Yap, L. Vidal, J. Adam, P. Stephens, J. Spicer et al., Phase I trial of the irreversible EGFR and HER2, 2010.

, kinase inhibitor BIBW 2992 in patients with advanced solid tumors, J Clin Oncol, vol.28, pp.3965-3972

W. Zhang, M. Gordon, A. M. Schultheis, D. Y. Yang, F. Nagashima et al., FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab, J Clin Oncol, vol.25, pp.3712-3718, 2007.

W. J. Zhou, D. Ercan, L. Chen, C. H. Yun, D. N. Li et al., Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature, vol.462, pp.1070-1074, 2009.

, License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited

, EMBO Molecular Medicine, vol.10, issue.2, 2017.